ESR1-Mutation Testing at First Progression in ER-Positive, HER2-Negative Advanced Breast Cancer

This infographic, the second in a three-part series, explores the prevalence of ESR1 mutations in patients with ER+/HER2- advanced breast cancer, as well as frequency of testing for ESR1 mutations in the metastatic setting; liquid biopsy as testing methodology; and ASCO, NCCN, and ESMO guidelines related to ESR1 mutations.